Search results for "Toxin"

showing 10 items of 1434 documents

Demonstration of High-Affinity Binding Sites for C3a Anaphylatoxin on Guinea-Pig Platelets

1978

3H-serotonin release from guinea-pig platelets was demonstrated to be the consequence of C3a binding to these cells. A Scatchard analysis of dose-response data of the 125I-C3a binding pattern to guinea-pig platelets pointed to the existence of binding sites with high and low affinity for the C3a molecule (HA and LA receptors). HA receptors are specific for C3a with intact C-terminal arginine. whereas C3adesarg only interacts with LA receptors. The release of serotonin may be induced by a combined reaction of C3a with HA receptors and LA receptors on the platelet membrane.

Blood PlateletsAnaphylatoxinsSerotoninBinding SitesArginineChemistryGuinea PigsImmunologyTemperaturechemical and pharmacologic phenomenaCarboxypeptidasesComplement C3General MedicineGuinea pigBiochemistryAnimalsProtease-activated receptorPlateletAnaphylatoxinSerotoninBinding sitePeptidesReceptorScandinavian Journal of Immunology
researchProduct

Comparative study on biological activities of various anaphylatoxins (C4a, C3a, C5a)

1981

Several anaphylatoxic substances (human C3a, guinea pig C3a, human C4a, guinea pig C5a, and a synthetic C3a-related hexapeptide) were compared with regard to their ability to induce secretion of [3H] serotonin from guinea pig platelets. Functional identity of the C3a preparations, C4a, and the hexapeptide was demonstrated by the phenomenon of crossed desensitization. Whereas C3a of human and guinea pig origin proved to be qualitatively and quantitatively identical, C4a expressed only 3% of the activity of the C3 fragments on a molar basis. Investigations with goat anti-guinea pig C3a demonstrate that human and guinea pig C3a possess one antigenic determinant in common; however, this determi…

Blood PlateletsAnaphylatoxinsSerotoninGuinea PigsImmunologyComplement C5achemical and pharmacologic phenomenaGuinea pigThrombinmedicineAnimalsHumansImmunology and AllergyPlateletAnaphylatoxinSecretionChemistryImmune SeraThrombinComplement C4aComplement C5Complement C4Biological activityComplement C3Complement System ProteinsIn vitroBiochemistryComplement C3aSerotoninPeptidesmedicine.drugInflammation
researchProduct

Platelet Activation: a New Biological Activity of Guinea-pig C3a Anaphylatoxin

1978

3H-serotonin-release from labelled gp-platelets is established as a sensitive method for testing a new biological activity of gp-C3a anaphylatoxin in an autologous situation. Time-, dose- and temperature-dependent release reactions as well as specific inhibition by carboxypeptidase B and anti-C3a antibodies show that C3a is a potent and specific inducer of platelet activation. Inactive C3a does not induce 3H-serotonin-release but specifically inhibits the action of C3a on platelets.

Blood PlateletsAnaphylatoxinsSerotoninTime FactorsGuinea PigsImmunologychemical and pharmacologic phenomenaTritiumGuinea pigComplement Inactivator ProteinsAnimalsPlateletAnaphylatoxinInducerPlatelet activationComplement Inactivator ProteinsbiologyChemistryTemperatureBiological activityComplement C3General MedicineChromium RadioisotopesBiochemistrybiology.proteinAntibodyPeptidesScandinavian Journal of Immunology
researchProduct

Comparative study on biological effects of the guinea pig complement-peptide C3a and C3a-related synthetic oligopeptides

1980

Dose-response experiments with guinea pig C3a and a synthetic hexapeptide (amino acid residues 72–77), representing the COOH-terminal sequence of human C3a, were performed in two recently described bioassay systems for C3a, i.e. cytotoxicity against tumor cells measured as LDH and 51Cr-release and non cytolytic serotonin release from guinea pig platelets. Compared to the classical anaphylatoxic assay (guinea pig ileum contraction), nearly identical reactivities were observed in all three test systems with C3a and, although quantitatively different, with hexapeptide.

Blood PlateletsCytotoxicity ImmunologicAnaphylatoxinsSerotoninContraction (grammar)ImmunologyDose-Response Relationship Immunologicchemical and pharmacologic phenomenaPeptideBiologyGuinea pigMiceAnimalsBioassayPlateletCytotoxicityMolecular Biologychemistry.chemical_classificationOligopeptideL-Lactate DehydrogenaseComplement C3Peptide Chain Termination TranslationalCytolysisBiochemistrychemistryBiological AssayOligopeptidesMolecular Immunology
researchProduct

Isolation and toxicity of Bacillus thuringiensis from potato-growing areas in Bolivia

2004

Bacillus thuringiensis was isolated from 116 samples collected in high altitude potato-growing areas in Bolivia. In these regions, main potato pests are the potato tuberworm Phthorimaea operculella, and the Andean weevils Premnotrypes latithorax and Rhigopsidius tucumanus. B. thuringiensis was found in 60% of the samples. The main percentage of samples with B. thuringiensis was found in larvae of R. tucumanus (78%). Bioassays were performed with 112 isolates. None resulted toxic to either larvae or adults of the two Andean weevils. However, 18 isolates from this study showed more toxicity against the beet armyworm Spodoptera exigua than the standard strain var. kurstaki isolated from DELFIN…

BoliviaVeterinary medicineBacterial ToxinsBacillus thuringiensisPolymerase Chain ReactionBacterial ProteinsBeet armywormBacillus thuringiensisExiguaBotanyAnimalsSoil MicrobiologyEcology Evolution Behavior and SystematicsSolanum tuberosumbiologyfungiDustbiology.organism_classificationGelechiidaePhthorimaea operculellaLepidopteraBiopesticideLarvaWeevilsElectrophoresis Polyacrylamide GelRestriction fragment length polymorphismPolymorphism Restriction Fragment LengthSolanaceaeJournal of Invertebrate Pathology
researchProduct

Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.

1996

The aim of this study was to investigate pertussis-specific cell-mediated immunity in infants vaccinated with a tricomponent acellular vaccine. Infants were investigated during a primary vaccination schedule from the third month of life to the sixth month as well as before and after a booster at 15 to 24 months. This is the first report of specific cell-mediated immune responses to pertussis-related antigens in infants below the age of 12 months. Our data show that the vaccine induces T-cell responses specific for the vaccine components, detoxified pertussis toxin, filamentous hemagglutinin, and pertactin, that increase progressively over the course of the vaccination schedule. In contrast …

Bordetella pertussisCellular immunityVaccination scheduleT-LymphocytesImmunologyLymphocyte ActivationMicrobiologyBordetella pertussisImmunophenotypingImmune systemImmunityHumansVirulence Factors BordetellaAntigens BacterialbiologyVaccinationInfantbiology.organism_classificationVirologyAntibodies BacterialVaccinationInfectious DiseasesPertussis ToxinImmunologyCytokinesParasitologyCytokine secretionPertactinResearch Article
researchProduct

Analogous IgG subclass response to pertussis toxin in vaccinated children, healthy or affected by whooping cough

2003

The study of antigen specific IgG subclass distribution during disease, or during any other natural or artificial immunisation, can provide useful information on the kind of the immune response and the expected levels of protection. This is particularly true for diseases, such as pertussis in which the mechanisms underlying specific defence are still not completely understood. An investigation was therefore performed to evaluate the IgG subclass response to pertussis toxin (PT) in sera from 89 healthy vaccinated children and 131 vaccinated or unvaccinated children convalescent after a confirmed B. pertussis symptomatic infection. Antibody titres were expressed in arbitrary ELISA units/ml, a…

Bordetella pertussisWhooping CoughEnzyme-Linked Immunosorbent AssayPertussis toxinBordetella pertussisSubclassImmune systemReference ValuesmedicineHumansChildWhooping coughPertussis VaccineGeneral VeterinaryGeneral Immunology and MicrobiologybiologyPublic Health Environmental and Occupational Healthmedicine.diseasebiology.organism_classificationAntibodies BacterialVirologyVaccinationInfectious DiseasesPertussis ToxinImmunoglobulin GHumoral immunityImmunologybiology.proteinMolecular MedicineAntibodyVaccine
researchProduct

Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine.

1994

The safety and immunogenicity of an acellular pertussis vaccine containing the genetically detoxified pertussis toxin PT-9K/129C, filamentous hemagglutinin, and pertactin, together with diphtheria and tetanus toxoids, were compared with those of a whole-cell pertussis component-diphtheria-tetanus vaccine. Four hundred eighty infants were enrolled into this prospective, multicenter, double-blind study. Each infant was randomly given three doses of one of the two vaccines at 2, 4, and 6 months of age. Both local and systemic adverse reactions, reported within 48 hours and 7 days of each injection, were less frequent after the acellular vaccine than after the whole-cell vaccine. The enzyme-lin…

Bordetella pertussisbiologybusiness.industryDiphtheriaFilamentous haemagglutinin adhesinbiology.organism_classificationmedicine.diseasePertussis toxincomplex mixturesVirologyVaccinationVaccino pertosse; immunogenicità; tossina; vaccinazione; bambiniPediatrics Perinatology and Child HealthImmunologymedicinePertussis vaccinePertactinBORDETELLA-PERTUSSISbusinessWhooping coughmedicine.drug
researchProduct

Preoperative preparation of «loss of domain» hernia. Progressive pneumoperitoneum and botulinum toxin type A.

2017

Preoperative progressive pneumoperitoneum and botulinum toxin type A are useful tools in the preparation of patients with loss of domain hernias. Both procedures are complementary in the surgical repair, especially with the use of prosthetic techniques without tension, that allow a integral management of these patients. The aim of this paper is to update concepts related to both procedures, emphasizing the advantages that take place in the preoperative management of loss of domain hernias.

Botulin toxinmedicine.medical_specialtyIncisional hernia030230 surgeryDomain (software engineering)03 medical and health sciences0302 clinical medicinePneumoperitoneumPreoperative CareMedicineHumansHerniaBotulinum Toxins Type ASurgical repairbusiness.industryGeneral Engineeringmedicine.diseaseBotulinum toxinSurgeryHernia Abdominal030220 oncology & carcinogenesisAnesthesiabusinessPneumoperitoneum Artificialmedicine.drugBotulinum toxin typeCirugia espanola
researchProduct

Salivary gland application of botulinum toxin for the treatment of sialorrhea

2007

Sialorrhea or excessive salivation, and drooling, are common and disabling manifestations in different neurological disorders. A review is made of the literature, based on a PubMed search, selecting those articles describing clinical trials involving the injection of botulinum toxin A in the salivary glands of patients with different diseases characterized by sialorrhea. The most frequently treated diseases were infant cerebral palsy (30%), Parkinson’s disease (20%) and amyotrophic lateral sclerosis (15%). Over half of the authors injected the product into the parotid glands, 9.5% into the submaxillary glands, and 38% into both. The total doses of toxin injected varied from 10-100 units of …

Botulinum toxinsalivary glandsToxina botulínicaUNESCO::CIENCIAS MÉDICASsialorreaglándulas salivales:CIENCIAS MÉDICAS [UNESCO]sialorrheaneurological diseasesenfermedades neurológicas
researchProduct